Literature DB >> 21852879

Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither?

Michael Wong.   

Abstract

Entities:  

Year:  2011        PMID： 21852879      PMCID： PMC3117496          DOI： 10.5698/1535-7511-11.2.66

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  14 in total

1.  mTOR in tuberous sclerosis and other neurological disorders.

Authors:  David Neal Franz
Journal:  Epilepsia       Date:  2007-08       Impact factor: 5.864

2.  Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?

Authors:  Ling-Hui Zeng; Sharon McDaniel; Nicholas R Rensing; Michael Wong
Journal:  Cell Cycle       Date:  2010-06-15       Impact factor: 4.534

3.  Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy.

Authors:  Paul S Buckmaster; Felicia H Lew
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

4.  Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.

Authors:  Stephan Rüegg; Marianna Baybis; Hal Juul; Marc Dichter; Peter B Crino
Journal:  Epilepsy Res       Date:  2007-11-05       Impact factor: 3.045

5.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

6.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

7.  Rapamycin: brain excitability studied in vitro.

Authors:  Delchad Daoud; Hans H Scheld; Erwin-Josef Speckmann; Ali Gorji
Journal:  Epilepsia       Date:  2007-02-05       Impact factor: 5.864

8.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

Review 9.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

10.  The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Michael Wong
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167
View more
  10 in total

1.  Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86.

Authors:  Mehmet Canpolat; Huseyin Per; Hakan Gumus; Ali Yikilmaz; Ekrem Unal; Turkan Patiroglu; Levent Cinar; Ali Kurtsoy; Sefer Kumandas
Journal:  Childs Nerv Syst       Date:  2013-06-07       Impact factor: 1.475

Review 2.  Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.

Authors:  Robin C C Ryther; Michael Wong
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 3.  Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.

Authors:  Bryan L Clossen; Doodipala Samba Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-05       Impact factor: 5.187

4.  Antiepileptic action of c-Jun N-terminal kinase (JNK) inhibition in an animal model of temporal lobe epilepsy.

Authors:  Tina Y Tai; Lindsay N Warner; Terrance D Jones; Sangwook Jung; Francis A Concepcion; David W Skyrud; Jason Fender; Yusha Liu; Aaron D Williams; John F Neumaier; Raimondo D'Ambrosio; Nicholas P Poolos
Journal:  Neuroscience       Date:  2017-02-22       Impact factor: 3.590

Review 5.  Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.

Authors:  Aristea S Galanopoulou; Jan A Gorter; Carlos Cepeda
Journal:  Epilepsia       Date:  2012-05-11       Impact factor: 5.864

Review 6.  The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis.

Authors:  Emilio Russo; Rita Citraro; Andrew Constanti; Giovambattista De Sarro
Journal:  Mol Neurobiol       Date:  2012-07-24       Impact factor: 5.682

7.  Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus.

Authors:  Yong-Zhi San; Yu Liu; Yu Zhang; Ping-Ping Shi; Yu-Lan Zhu
Journal:  Mol Med Rep       Date:  2015-04-17       Impact factor: 2.952

8.  Perspective: Therapeutic Potential of Flavonoids as Alternative Medicines in Epilepsy.

Authors:  Jae Young Kwon; Min-Tae Jeon; Un Ju Jung; Dong Woon Kim; Gyeong Joon Moon; Sang Ryong Kim
Journal:  Adv Nutr       Date:  2019-09-01       Impact factor: 8.701

9.  The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.

Authors:  Adam L Hartman; Polan Santos; Alison Dolce; J Marie Hardwick
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Kainic Acid Induces mTORC1-Dependent Expression of Elmo1 in Hippocampal Neurons.

Authors:  Magdalena Blazejczyk; Matylda Macias; Michal Korostynski; Marcelina Firkowska; Marcin Piechota; Agnieszka Skalecka; Aleksandra Tempes; Alicja Koscielny; Malgorzata Urbanska; Ryszard Przewlocki; Jacek Jaworski
Journal:  Mol Neurobiol       Date:  2016-03-19       Impact factor: 5.590
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.